Real-World Attainment of Guideline-Recommended Lipid Targets in Patients with High and Very High Cardiovascular Risk: A Prospective 12-Month Observational Cohort Study
Authors:
- Gabriela OtimanGOGabriela Otiman
- Ciprian Ilie RoscaCiprian Ilie Rosca
- Daniel Dumitru NisulescuDaniel Dumitru Nisulescu
- Abdeldayem MahmoudAMAbdeldayem Mahmoud
- Ana-Maria PahAPAna-Maria Pah
- Dana Emilia VelimroviciDVDana Emilia Velimrovici
- Cristina PlesCPCristina Ples
- Gheorghe Stoicescu-HogeaGSGheorghe Stoicescu-Hogea
Open Access
- 17 July 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5627
Abstract
Background/Objectives: European guidelines recommend increasingly stringent, risk-stratified low-density lipoprotein cholesterol (LDL-C) targets, but real-world attainment remains suboptimal. We evaluated 12-month lipid-target attainment and changes in model-derived cardiovascular risk estimates in an ambulatory dyslipidaemia cohort. Methods: In this prospective, single-centre observational study, 101 consecutive adults were assessed at baseline and after at least 12 months of routine-care lipid-lowering therapy. Patients were classified as moderate/low, high, or very high cardiovascular risk. The primary endpoint was attainment of the risk-specific LDL-C target at 12 months versus baseline. Paired changes were tested using the McNemar exact and Wilcoxon signed-rank tests. Multivariable logistic regression assessed correlates of target attainment, with Firth penalisation used because of sparse outcomes in the higher risk strata. Results: LDL-C target attainment increased from 6.0% to 43.0%, and non-HDL-C attainment from 7.0% to 51.5% (both p < 0.001). At 12 months, 89% of moderate/low-risk patients reached the LDL-C target, compared with 9% of high-risk and 23% of very-high-risk patients (p < 0.001). Higher risk category was strongly associated with non-attainment, although the odds ratios were imprecise because of sparse events. Only one patient received a high-intensity statin and three received a PCSK9 inhibitor, despite 63% of the cohort being at high or very high risk. Model-derived risk scores decreased, partly as a mathematical consequence of updated lipid inputs. Therapy was well tolerated. Conclusions: Lipid control improved substantially, but target attainment remained poorest in patients at greatest cardiovascular risk. Earlier treatment intensification, structured adherence assessment, and more consistent use of combination therapy may reduce this implementation gap.Keywords
Funding Information
- Victor Babes University of Medicine and Pharmacy Timisoara (Victor Babeș University of Medicine and Pharmacy Timișoara)
This publication has 36 references indexed in Scilit:
- Low-Density Lipoprotein Cholesterol Levels and Bleeding Risk in Venous ThromboembolismJAMA Network Open, 2025
- Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI studyThe Lancet Regional Health - Europe, 2023
- Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational studyAtherosclerosis, 2021
- Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)Pharmacological Research, 2021
- Apolipoprotein B Particles and Cardiovascular DiseaseJAMA Cardiology, 2019
- Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and PreferencesJAMA Cardiology, 2018
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic InterventionsJAMA, 2016
- Triglycerides and cardiovascular diseaseThe Lancet, 2014
- The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trialsThe Lancet, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010